vs
中国东方航空（EML）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
中国东方航空的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.6倍（$55.3M vs $35.5M），中国东方航空净利率更高（1.0% vs -304.2%，领先305.3%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -22.4%），中国东方航空自由现金流更多（$3.1M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -0.6%）
中国东方航空是中国境内的头部航空公司，总部位于上海长宁区，与中国国际航空、中国南方航空并称为中国三大骨干航空公司，航线网络覆盖全球多个国家和地区，是中国民航市场的核心运营商之一。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
EML vs RXRX — 直观对比
营收规模更大
EML
是对方的1.6倍
$35.5M
营收增速更快
RXRX
高出704.1%
-22.4%
净利率更高
EML
高出305.3%
-304.2%
自由现金流更多
EML
多$50.4M
$-47.3M
两年增速更快
RXRX
近两年复合增速
-0.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $55.3M | $35.5M |
| 净利润 | $578.9K | $-108.1M |
| 毛利率 | 22.3% | 59.8% |
| 营业利润率 | 3.1% | -304.8% |
| 净利率 | 1.0% | -304.2% |
| 营收同比 | -22.4% | 681.7% |
| 净利润同比 | 103.8% | 39.6% |
| 每股收益（稀释后） | $0.10 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMLRXRX
| Q4 25 | — | $35.5M | ||
| Q3 25 | $55.3M | $5.2M | ||
| Q2 25 | $70.2M | $19.2M | ||
| Q1 25 | $63.3M | $14.7M | ||
| Q4 24 | $64.3M | $4.5M | ||
| Q3 24 | $71.3M | $26.1M | ||
| Q2 24 | $72.6M | $14.4M | ||
| Q1 24 | $64.6M | $13.8M |
净利润EMLRXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $578.9K | $-162.3M | ||
| Q2 25 | $3.4M | $-171.9M | ||
| Q1 25 | $1.9M | $-202.5M | ||
| Q4 24 | $1.3M | $-178.9M | ||
| Q3 24 | $-15.3M | $-95.8M | ||
| Q2 24 | $3.5M | $-97.5M | ||
| Q1 24 | $1.9M | $-91.4M |
毛利率EMLRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | 22.3% | -183.8% | ||
| Q2 25 | 23.3% | -4.9% | ||
| Q1 25 | 22.4% | -48.0% | ||
| Q4 24 | 23.6% | -181.4% | ||
| Q3 24 | 25.5% | 53.7% | ||
| Q2 24 | 25.4% | 36.2% | ||
| Q1 24 | 23.9% | 19.1% |
营业利润率EMLRXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | 3.1% | -3327.6% | ||
| Q2 25 | 4.5% | -916.8% | ||
| Q1 25 | 5.1% | -1297.9% | ||
| Q4 24 | 6.1% | -4042.4% | ||
| Q3 24 | 9.5% | -377.1% | ||
| Q2 24 | 8.3% | -697.4% | ||
| Q1 24 | 5.3% | -698.4% |
净利率EMLRXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | 1.0% | -3135.3% | ||
| Q2 25 | 4.9% | -894.2% | ||
| Q1 25 | 3.1% | -1373.3% | ||
| Q4 24 | 2.0% | -3935.5% | ||
| Q3 24 | -21.5% | -367.5% | ||
| Q2 24 | 4.8% | -676.6% | ||
| Q1 24 | 3.0% | -662.4% |
每股收益（稀释后）EMLRXRX
| Q4 25 | — | $-0.17 | ||
| Q3 25 | $0.10 | $-0.36 | ||
| Q2 25 | $0.56 | $-0.41 | ||
| Q1 25 | $0.32 | $-0.50 | ||
| Q4 24 | $0.22 | $-0.56 | ||
| Q3 24 | $-2.46 | $-0.34 | ||
| Q2 24 | $0.56 | $-0.40 | ||
| Q1 24 | $0.31 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.2M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $124.3M | $1.1B |
| 总资产 | $220.0M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资EMLRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | $9.2M | $659.8M | ||
| Q2 25 | $9.1M | $525.1M | ||
| Q1 25 | $10.2M | $500.5M | ||
| Q4 24 | $16.1M | $594.4M | ||
| Q3 24 | $9.7M | $427.6M | ||
| Q2 24 | $2.0M | $474.3M | ||
| Q1 24 | $2.1M | $296.3M |
总债务EMLRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $42.2M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益EMLRXRX
| Q4 25 | — | $1.1B | ||
| Q3 25 | $124.3M | $1.0B | ||
| Q2 25 | $124.4M | $919.1M | ||
| Q1 25 | $121.0M | $933.9M | ||
| Q4 24 | $120.7M | $1.0B | ||
| Q3 24 | $119.2M | $524.6M | ||
| Q2 24 | $136.5M | $584.4M | ||
| Q1 24 | $134.5M | $401.2M |
总资产EMLRXRX
| Q4 25 | — | $1.5B | ||
| Q3 25 | $220.0M | $1.4B | ||
| Q2 25 | $229.4M | $1.3B | ||
| Q1 25 | $232.3M | $1.3B | ||
| Q4 24 | $235.3M | $1.4B | ||
| Q3 24 | $244.2M | $726.5M | ||
| Q2 24 | $255.9M | $775.9M | ||
| Q1 24 | $253.9M | $557.8M |
负债/权益比EMLRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.35× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $3.1M | $-47.3M |
| 自由现金流率自由现金流/营收 | 5.5% | -133.1% |
| 资本支出强度资本支出/营收 | 0.1% | 3.5% |
| 现金转化率经营现金流/净利润 | 5.38× | — |
| 过去12个月自由现金流最近4个季度 | $12.3M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流EMLRXRX
| Q4 25 | — | $-46.1M | ||
| Q3 25 | $3.1M | $-117.4M | ||
| Q2 25 | $3.8M | $-76.4M | ||
| Q1 25 | $-1.8M | $-132.0M | ||
| Q4 24 | $11.0M | $-115.4M | ||
| Q3 24 | $-2.9M | $-59.2M | ||
| Q2 24 | $8.4M | $-82.2M | ||
| Q1 24 | $2.8M | $-102.3M |
自由现金流EMLRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | $3.1M | $-117.6M | ||
| Q2 25 | $3.0M | $-79.6M | ||
| Q1 25 | $-2.7M | $-133.8M | ||
| Q4 24 | $9.0M | $-116.7M | ||
| Q3 24 | $-7.7M | $-63.8M | ||
| Q2 24 | $7.3M | $-83.4M | ||
| Q1 24 | $1.1M | $-109.0M |
自由现金流率EMLRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | 5.5% | -2272.5% | ||
| Q2 25 | 4.3% | -413.9% | ||
| Q1 25 | -4.3% | -907.4% | ||
| Q4 24 | 13.9% | -2567.7% | ||
| Q3 24 | -10.8% | -244.6% | ||
| Q2 24 | 10.1% | -578.5% | ||
| Q1 24 | 1.7% | -789.9% |
资本支出强度EMLRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | 0.1% | 4.7% | ||
| Q2 25 | 1.1% | 16.4% | ||
| Q1 25 | 1.3% | 12.4% | ||
| Q4 24 | 3.2% | 28.6% | ||
| Q3 24 | 6.7% | 17.5% | ||
| Q2 24 | 1.5% | 8.2% | ||
| Q1 24 | 2.6% | 48.2% |
现金转化率EMLRXRX
| Q4 25 | — | — | ||
| Q3 25 | 5.38× | — | ||
| Q2 25 | 1.09× | — | ||
| Q1 25 | -0.95× | — | ||
| Q4 24 | 8.41× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.40× | — | ||
| Q1 24 | 1.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
